Pubblicazioni

Autori:

Carta, Sara; Tiberi, Riccardo; De Rossi, Nicola; Maniscalco, Giorgia Teresa; Greco, Giacomo; Lotti, Antonio; Marziali, Alessandro; Sartori, Arianna; Favero, Anna; Rossi, Francesca; Dinoto, Alessandro; Trentinaglia, Milena; Chiodega, Vanessa; Boso, Federica; Miante, Silvia; De Biase, Stefano; Caleri, Francesca; Orlandi, Riccardo; Guso, Enis; Volonghi, Irene; Nosadini, Margherita; Sartori, Stefano; Palmieri, Pasqualina; Cossu, Alberto; Calabria, Francesca; Zara, Pietro; Giannoccaro, Maria Pia; Zuliani, Luigi; Vianello, Marika; De Luca, Giovanna; Zoccarato, Marco; De Mauro, Anna; Massacesi, Luca; Cortese, Rosa; Gajofatto, Alberto; Rossi, Patrizia; Sechi, Elia; Vogrig, Alberto; Damato, Valentina; Gastaldi, Matteo; Mariotto, Sara

Titolo:

Validation of the MOG-AR Score: A Retrospective Multicenter Study

Anno:

2026

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

Elettronico

Referee:

Sì

Nome rivista:

NEUROLOGY® NEUROIMMUNOLOGY & NEUROINFLAMMATION

ISSN Rivista:

2332-7812

N° Volume:

13

Numero o Fascicolo:

2

Intervallo pagine:

1-6

Parole chiave:

MOGAD; patient; relapse risk; MOG-AR Score; immunosuppressive treatment

Breve descrizione dei contenuti:

Objectives: A score evaluating age at onset, sex, clinical phenotype, and treatment received (MOG-AR) has been proposed to identify MOGAD patients at high relapse risk. The aim of this study was to validate the MOG-AR score in a multicenter cohort and to assess other variables potentially associated with relapses. Methods: MOGAD patients were retrospectively enrolled from 24 centers. The MOG-AR score was applied and 4 categories of relapse risk were identified (grade I: lowest risk; grade IV: highest risk), accordingly. The association of MOG-AR score and additional variables with a relapsing course were then explored. Results: Of 190 included patients, the median age at onset was 37 [IQR 23-51] years and 107 (56%) were female. A total of 78 patients (41%) experienced a relapse during a median of 43.6 months [24.8-75.4]. Using the proposed cutoff of 9, the MOG-AR score had a sensitivity of 53.9% [95% CI 55.6-73.9] and a specificity of 65.18% [95% CI 55.60-73.93]; area under the curve: 0.64 (95% CI 0.57-0.72). Among additional investigated factors, only immunosuppressive treatment after the presenting MOGAD attack was associated with a lower relapse risk. Discussion: MOG-AR score failed to accurately predict a relapsing disease course. Only immunosuppressive treatment after the first event was significantly associated with a lower relapse risk.

Pagina Web:

https://doi.org/10.1212/NXI.0000000000200547

Id prodotto:

149494

Handle IRIS:

11562/1181314

ultima modifica:

21 marzo 2026

Citazione bibliografica:

Carta, Sara; Tiberi, Riccardo; De Rossi, Nicola; Maniscalco, Giorgia Teresa; Greco, Giacomo; Lotti, Antonio; Marziali, Alessandro; Sartori, Arianna; Favero, Anna; Rossi, Francesca; Dinoto, Alessandro; Trentinaglia, Milena; Chiodega, Vanessa; Boso, Federica; Miante, Silvia; De Biase, Stefano; Caleri, Francesca; Orlandi, Riccardo; Guso, Enis; Volonghi, Irene; Nosadini, Margherita; Sartori, Stefano; Palmieri, Pasqualina; Cossu, Alberto; Calabria, Francesca; Zara, Pietro; Giannoccaro, Maria Pia; Zuliani, Luigi; Vianello, Marika; De Luca, Giovanna; Zoccarato, Marco; De Mauro, Anna; Massacesi, Luca; Cortese, Rosa; Gajofatto, Alberto; Rossi, Patrizia; Sechi, Elia; Vogrig, Alberto; Damato, Valentina; Gastaldi, Matteo; Mariotto, Sara, Validation of the MOG-AR Score: A Retrospective Multicenter Study «NEUROLOGY® NEUROIMMUNOLOGY & NEUROINFLAMMATION» , vol. 13 , n. 2 , 2026 , pp. 1-6

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo